Stem cells have the potential to differentiate into a wide variety of specialized cell types. They can be used for basic research, drug discovery and, ultimately, for the treatment and prevention of disease. However, a major obstacle is that human embryonic stem (hES) cells are derived from the inner cell mass of blastocysts and derivation is encumbered by political and ethical dilemmas. Additionally, human embryonic stem cells have been found to be tumorgenic when injected into immunologically-impaired animals. Furthermore, while human embryonic stem cells potentially differentiate into multiple types of functional cells in vivo, controlled, large-scale differentiation of hES cells into specific cell types in culture has not yet been definitively demonstrated.
Scientists at UC San Diego have developed methods for isolating, identifying, expanding, and differentiating a novel source of epithelioid multipotent amniotic fetal stem cells with typical hES markers. The isolated stem cells have been characterized and have been shown to express typical hES-cell markers (characterized by expression of SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, Oct-4, CD105, and SSEA1).
The technology provides a method for preparing multipotent stem cells from amniotic fluid and includes harvesting from amniotic fluid; culturing, identifying, and isolating epithelioid stem-cells; and expanding the cells to an undifferentiated state. The number of differentiated pathways and the control of these pathways in culture suggest widespread applications of the new cells.
See U.S. Letters Patent 7,569,385.
|United States Of America||Issued Patent||7,569,385||08/04/2009||2005-041|
|Patent Cooperation Treaty||Reference for National Filings||WO2005017117||02/24/2005||2005-041|
Additional Patent Pending